ATRS
Antares Pharma Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
Antares Pharma, Inc. is a pharmaceutical technology company focused primarily on the development and commercialization of self-administered injectable pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), Covis Pharma (Covis), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia). Antares Pharma's FDA-approved products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva. The Company also markets NOCDURNA® (desmopressin acetate) in the U.S., which was licensed from Ferring Pharmaceuticals.
Market Cap: 955 Million
Primary Exchange: NASDAQ
Website: www.antarespharma.com
Shares Outstanding: 171 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.7615867238410275
Sector: Manufacturing
Industry: Surgical and Medical Instrument Manufacturing
Ethical Flags
Longest drawdown: 1486 trading days
From: 2014-01-10 To: 2019-11-29
Lowest Point:
Antares Pharma: What The Market Is Missing
via: SeekingAlpha at 2019-06-11 01:18:27:000
As the chart below illustrates, Antares Pharma ( ATRS ) stock has been down and under pressure since the FDA approval of Clarus Therapeutics' TRT drug Jatenzo on March 28, which gives an indication of lower investor sentiment and expectations. (Courtesy StockCharts.com) After reaching an i… read more...
Antares Pharma: What The Market Is Missing
via: SeekingAlpha at 2019-06-11 01:18:27:000
As the chart below illustrates, Antares Pharma ( ATRS ) stock has been down and under pressure since the FDA approval of Clarus Therapeutics' TRT drug Jatenzo on March 28, which gives an indication of lower investor sentiment and expectations. (Courtesy StockCharts.com) After reaching an i… read more...
Antares Pharma: What The Market Is Missing
via: SeekingAlpha at 2019-06-11 01:18:27:000
As the chart below illustrates, Antares Pharma ( ATRS ) stock has been down and under pressure since the FDA approval of Clarus Therapeutics' TRT drug Jatenzo on March 28, which gives an indication of lower investor sentiment and expectations. (Courtesy StockCharts.com) After reaching an i… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|